AI-generated summary
The authors ran a blind, randomized, placebo-controlled split-face trial of low-fluence Q-switched Nd:YAG laser for melasma, with both sides receiving combination topical therapy. Both the laser-treated and control sides showed similar decreases in melanin index and mMASI scores, and the authors conclude the laser added no significant benefit beyond topical therapy.
- Who or what was studied
- Patients with melasma and Fitzpatrick skin types I-IV, with melasma severity scores of at least 2
- Limits stated in the abstract
- The abstract does not state the number of patients enrolled, so the sample size is unclear.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on journals.lww.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 1064 nm, 064 nm
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Fluence, Laser, Placebo-controlled, Melanin. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.